Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
28 recruiting
Showing 1–20 of 41 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Non-small Cell Lung CancerAdvanced Non-Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+3 more
ArriVent BioPharma, Inc.480 enrolled78 locationsNCT07185997
Recruiting
Phase 1Phase 2
DIAG723 in Adults With Hereditary Hemorrhagic Telangiectasia
Pulmonary Arterial HypertensionHereditary hemorrhagic telangiectasia
Diagonal Therapeutics, Inc.93 enrolled5 locationsNCT07623525
Recruiting
Phase 2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Advanced Microsatellite Stable Colorectal Cancer
Gilead Sciences170 enrolled14 locationsNCT07527858
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled266 locationsNCT07213804
Recruiting
Phase 3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Colorectal Neoplasms
Seagen, a wholly owned subsidiary of Pfizer400 enrolled366 locationsNCT05253651
Recruiting
Phase 3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Non-small Cell Lung CancerNSCLCNSCLC (Advanced Non-small Cell Lung Cancer)+2 more
Revolution Medicines, Inc.590 enrolled152 locationsNCT06881784
Recruiting
Phase 2
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NeoplasmsAdolescentChild
Eli Lilly and Company105 enrolled73 locationsNCT05999994
Recruiting
Phase 1Phase 2
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Advanced Lung Cancer
BioNTech SE594 enrolled88 locationsNCT06892548
Recruiting
Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma
Retroperitoneal Liposarcoma
Australia and New Zealand Sarcoma Association100 enrolled13 locationsNCT07377747
Recruiting
Phase 2
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Esophageal AdenocarcinomaGastric AdenocarcinomaHER2-negative+1 more
Gilead Sciences120 enrolled4 locationsNCT07546812
Recruiting
Phase 3
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Endometrial CancerRecurrent or Progressive Endometrial Cancer
Genmab660 enrolled120 locationsNCT07166094
Recruiting
Phase 1Phase 2
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
MTAP-deleted Solid Tumors
Bayer450 enrolled60 locationsNCT06914128
Recruiting
Metastatic Leiomyosarcoma Biomarker Protocol
Leiomyosarcoma
University of Michigan Rogel Cancer Center200 enrolled11 locationsNCT05653388
Recruiting
Phase 1Phase 2
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Ottimo Pharma Limited170 enrolled12 locationsNCT07266428
Recruiting
Phase 1
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
SarcomaNon-small Cell Lung CancerNSCLC+12 more
Epkin146 enrolled10 locationsNCT06789172
Recruiting
Phase 2
A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)
Carcinoma, Non-Small Cell Lung
Bristol-Myers Squibb130 enrolled70 locationsNCT06855771
Recruiting
Not Applicable
PRIORITY-CONNECT 2 Trial
Colorectal, CancerColorectal Neoplasms
Surgical Outcomes Research Centre (SOuRCe)564 enrolled31 locationsNCT06976710
Recruiting
Phase 3
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.
Non-small Cell Lung Cancer
ETOP IBCSG Partners Foundation290 enrolled42 locationsNCT06284317
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled85 locationsNCT06172478
Recruiting
Phase 2
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Cholangiocarcinoma
Australasian Gastro-Intestinal Trials Group40 enrolled8 locationsNCT06441747